Revvity 

€0
119
+€0+0% 今天

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

即將到來

股息

0%股息殖利率
Feb 26
€0.06
Nov 25
€0.06
Aug 25
€0.06
May 25
€0.06
Feb 25
€0.07
10年成長
-0.01%
5年成長
0.08%
3年成長
-2.18%
1年成長
-3.59%

財報

29Jan預期
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
0.83
1.01
1.19
1.37
預期EPS
1.3402317609999999
實際EPS
不適用

財務

9.81%利潤率
有盈利
2019
2020
2021
2022
2023
2024
2.56B營收
250.99M淨利

分析師評級

$84.01平均目標價
最高預估為 93.33。
來自過去6個月內的 8 則評分。這不是投資建議。
買入
38%
持有
63%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 1RVTY.MI 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Show more...
執行長
Dr. Prahlad R. Singh Ph.D.
員工
16000
國家
United States
ISIN
US7140461093

上市

0 Comments

分享你的想法

FAQ

Revvity 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Revvity 的股票以代號 1RVTY.MI 進行交易。
Revvity 去年的營收是多少?
Revvity 去年的營收為 2.56BEUR。
Revvity 去年的淨利是多少?
1RVTY.MI 去年的淨收益為 250.99MEUR。
Revvity 會發放股息嗎?
是的,1RVTY.MI 的股息每 每季 發放一次。每股最新股息為 0.06 EUR。截至今日,股息殖利率(FWD)% 為 0%。
Revvity 有多少名員工?
截至 April 05, 2026,公司共有 16,000 名員工。
Revvity 位於哪個產業?
Revvity從事於Healthcare產業。
Revvity 何時完成拆股?
Revvity 最近沒有進行任何拆股。
Revvity 的總部在哪裡?
Revvity 的總部位於 United States 的 Waltham。